The significant association of d16HER2 expression and positive lymph nodes (p < 0.0001) in their cohort implicated d16HER2 as a clinically important and tumor-specific molecular alteration of HER2 that promoted aggressive, locally disseminated metastatic BC. Here, ERBB2 is linked to neoplasm.